What Happened?
Boston, -based Inozyme Resigned Kevin Johnson as Senior Vice President of Global Regulatory Affairs, Quality and Product Development
About the Company
We are a biopharmaceutical company specializing in the development of novel therapeutics to treat rare metabolic diseases. Our lead product candidate is INZ-701, an enzyme replacement therapy (ERT) in the early stages of clinical development for the potential treatment of patients with a variety of calcification disorders linked primarily to mutations in the ENPP1 and ABCC6 genes, or ENPP1 Deficiency and ABCC6 Deficiency respectively. We have demonstrated proof of concept with INZ-701 in both GACI and ARHR2 two phenotypes of ENPP1 Deficiency.
About the Person
Kevin B. Johnson is Chief Regulatory Officer at Ring Therapeutics. Previously, Kevin held various senior legal leadership roles in the industry.
Info Source
News
Short Profile